1. Clinical & Scientific Overview
Alfacalcidol (TIP-MED-000389, Reference Code [10.14]-C119) is classified under
Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Co-indexed constituent under primary monograph [10.14] (Calcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.14], p. 133): Calcitriol: Rocaltrol (Abbott), Gemsoline (Macmillon), Calcitrol (Cadila). Alfacalcidol: One-Alpha (Leo), Alpha D3 (Panacea) — Strengths & Dosage Forms: Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
3. Mechanism of Action & Pharmacodynamics
Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H) for Secondary hyperparathyroidism and renal osteodystrophy (CKD-MBD) in CKD Stage 3b–5 and dialysis (where failed kidneys lack 1-alpha-hydroxylase to convert plain Cholecalciferol into active 1,25-(OH)2-D3!); post-thyroidectomy / idiopathic hypoparathyroidism; severe hypocalcaemia prophylaxis prior to Denosumab in advanced CKD.
4. Therapeutic Indications & Evidence-Supported Uses
- Secondary hyperparathyroidism and renal osteodystrophy (CKD-MBD) in CKD Stage 3b–5 and dialysis (where failed kidneys lack 1-alpha-hydroxylase to convert plain Cholecalciferol into active 1,25-(OH)2-D3!)
- post-thyroidectomy / idiopathic hypoparathyroidism
- severe hypocalcaemia prophylaxis prior to Denosumab in advanced CKD
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: CKD-MBD Secondary Hyperparathyroidism: Start 0.25 mcg PO Once Daily (or 0.25 mcg on alternate days if baseline calcium is high-normal); titrate every 4–8 weeks based on intact PTH (iPTH) and corrected Serum Calcium. Hypoparathyroidism: 0.5–2.0 mcg PO OD (alongside elemental Calcium 1000–2000 mg/day)
Administration & Meal Timing: May be taken with or without food | Morning or Bedtime (Once Daily or Thrice Weekly on dialysis days)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [10.14].
Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment
Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment
Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment
7. Contraindications, Precautions & High-Risk Warnings
- CRITICAL DISTINCTION FROM PLAIN CHOLECALCIFEROL (VITAMIN D3 60,000 IU): Calcitriol (0.25 mcg) and Alfacalcidol bypass renal 1-alpha-hydroxylase regulation and have a narrow therapeutic window — NEVER prescribe Calcitriol for simple nutritional Vitamin D deficiency in healthy patients (use Cholecalciferol 60,000 IU weekly x 8w instead!)! Contraindicated in hypercalcaemia (Ca2+ >10.2–10.5 mg/dL) and uncontrolled hyperphosphataemia
Key Clinical Precautions: Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment
8. Adverse Effects Profile
- Hypercalcaemia (30% if unmonitored!), hypercalciuria, hyperphosphataemia (Calcitriol increases intestinal absorption of BOTH calcium AND phosphate!)
- Severe hypercalcaemia (thirst, polyuria, constipation, confusion, lethargy, pancreatitis, QTc shortening, arrhythmias, acute kidney injury), vascular and soft-tissue calcification (when Calcium x Phosphate product >55 mg2/dL2!)
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Thiazide diuretics (Chlorthalidone, HCTZ, Indapamide) decrease urinary calcium excretion and precipitate severe hypercalcaemia with Calcitriol!; Hypercalcaemia triggers fatal Digoxin arrhythmias!; Magnesium-containing antacids/laxatives + Calcitriol in dialysis = severe hypermagnesaemia; Cholestyramine/Sevelamer reduce absorption (space by >=2h)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.14].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: COUNTER SAFETY CHECK: Verify whether the doctor wrote 'Cholecalciferol' (nutritional Vit D3) or 'Calcitriol 0.25 mcg' (active kidney hormone Rocaltrol/Gemsoline); on Calcitriol, get a monthly blood calcium and phosphorus test, and report excessive thirst, frequent urination, constipation, or confusion immediately
- Meal & Clock Timing Instruction: May be taken with or without food (Morning or Bedtime (Once Daily or Thrice Weekly on dialysis days))
- Missed Dose Protocol: Take same day if remembered; never double dose
- Geriatric Dispensing Pearl: Monitor serum calcium and renal function closely in older adults, especially if taking Calcium Carbonate or Thiazide diuretics
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.18]-C126 Oral Potassium Citrate Solution — Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelat
- [10.20]-C127 Calcium Polystyrene Sulfonate — Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassi
- [10.20]-C128 Sodium Zirconium Cyclosilicate — Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassi
- [10.14] Calcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism) — Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalcif